Structural and Functional Characterization of Hirudin P6 Derived Novel Bivalent Thrombin Inhibitors - Studying the Effect of Linker Length and Glycosylation on Their Function
Research article published in Chemical biology & drug design (2016)
Abstract
HirudinP6 is a glycosylated and sulfated high affinity thrombin inhibitory protein isolated from Hirudineria manillensis. In this study, designing of novel bivalent thrombin inhibitory peptides based on this hirudin isoform is described. The structural and functional impact of varying linker length and glycosylation on their inhibitory potencies and binding kinetics were assessed. The bivalent peptides were obtained by tethering an active site blocking fPRP motif with the carboxy terminal 22 residue segment of hirudin P6 (HP642-63 ) by varying number of glycine residues in the linker region. Among them, analog BiG1 -HP6 inhibited thrombin with a Ki of 5.12 nm which was comparable to that of glycosylated (disaccharide bearing) and non-sulfated full length hirudin P6 protein (Ki = 6.38 nm). Binding kinetics studies revealed increasing linker length can decrease the association rates of peptide─thrombin interactions. Similarly, glycosylation was found to negatively modulate the inhibitory potencies of these peptides by decreasing their rates of association with thrombin. Molecular docking studies revealed that increasing linker length can compromise the electrostatic interactions with the prime subsite residues of thrombin and provided structural explanation for the observed effect of linker length on association rates. These findings thus enhance our understanding of thrombin─(glyco)peptide interactions and provide key insights into the designing of efficient thrombin inhibitors and allosteric modulators of therapeutic potential.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed research on leech salivary pharmacology and bioactive peptides relevant to anticoagulation. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
Working from HirudinP6, a glycosylated and sulfated high-affinity thrombin inhibitor isolated from the leech Hirudineria manillensis, this study designed novel bivalent thrombin-inhibitory peptides by tethering an active-site-blocking fPRP motif to the hirudin C-terminal 22-residue segment via glycine linkers and assessed how linker length and glycosylation affect potency and binding kinetics; the lead analog (BiG1-HP6) inhibited thrombin with a Ki of 5.12 nM, comparable to the full-length glycosylated protein (Ki = 6.38 nM), while longer linkers and glycosylation reduced thrombin association rates, with molecular docking offering a structural explanation. This is directly relevant to the medicinal-leech secretome drug-discovery story: it shows how a leech-derived hirudin isoform can serve as a template for rationally engineered, high-affinity thrombin inhibitors and clarifies structure-function rules for designing such molecules. The key caveat is that these are in-vitro biochemistry, kinetics, and computational-docking experiments on engineered peptides, with no animal or clinical testing, so the findings inform anticoagulant design rather than any clinical leech-therapy claim.
Citation
Structural and Functional Characterization of Hirudin P6 Derived Novel Bivalent Thrombin Inhibitors - Studying the Effect of Linker Length and Glycosylation on Their Function.
Shabareesh et al. · Chemical biology & drug design, 2016
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026